Fortrea Holdings (FTRE) Operating Expenses (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Operating Expenses came in at $663.4 million in Q2 2026, down 36.25% YoY from $1.0 billion in Q2 2025, and up 3.67% on a QoQ basis from $639.9 million in Q1 2026.
Fortrea Holdings (FTRE) Operating Expenses (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Operating Expenses data on file, last reported at $663.4 million in Q2 2026.
- Quarterly Operating Expenses fell 36.25% year-over-year to $663.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.7 billion (down 26.53% YoY) and the FY2025 annual result came in at $3.6 billion, up 25.81% from the prior year.
- Operating Expenses grew to $663.4 million in Q2 2026, from $639.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $1.2 billion in Q1 2025 to a low of $488.3 million in Q4 2022.
- A 5-year average of $733.6 million and a median of $699.5 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2025 — Operating Expenses jumped 67.46% — and 2026, when it slumped 45.37%.
- Tracing FTRE's Operating Expenses over 5 years: stood at $488.3 million in 2022, then soared by 50.26% to $733.7 million in 2023, then grew by 2.58% to $752.6 million in 2024, then fell by 10.43% to $674.1 million in 2025, then slipped by 1.59% to $663.4 million in 2026.
- The last three Operating Expenses figures came in at $663.4 million (Q2 2026), $639.9 million (Q1 2026), and $674.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 663.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 663.40 Mn |
| Mar 31, 2026 | 639.90 Mn |
| Dec 31, 2025 | 674.10 Mn |
| Sep 30, 2025 | 709.90 Mn |
| Jun 30, 2025 | 1.04 Bn |
| Mar 31, 2025 | 1.17 Bn |
| Dec 31, 2024 | 752.60 Mn |
| Sep 30, 2024 | 692.90 Mn |
| Jun 30, 2024 | 713.30 Mn |
| Mar 31, 2024 | 699.50 Mn |
| Dec 31, 2023 | 733.70 Mn |
| Sep 30, 2023 | 703.50 Mn |
| Jun 30, 2023 | 693.50 Mn |
| Mar 31, 2023 | 679.80 Mn |
| Dec 31, 2022 | 488.30 Mn |
| Sep 30, 2022 | 693.40 Mn |
| Jun 30, 2022 | 721.90 Mn |